The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

被引：0
|
作者：
C. J. Currie
C. D. Poole
E. A. M. Gale
机构：
[1] Cardiff University,School of Medicine
[2] The Pharma Research Centre,Department of Epidemiology
[3] Cardiff MediCentre,Diabetes and Metabolism, School of Medicine
[4] Pharmatelligence,undefined
[5] Bristol University,undefined
来源：
Diabetologia | 2009年 / 52卷
关键词：
Cancer; Insulin; Insulin analogues; Metformin; Sulfonylureas; Survival; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1766 / 1777
页数：11
相关论文
共 50 条
  • [31] Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
    Nissaisorakarn, Pitchaphon
    Pavlakis, Martha
    Aala, Amtul
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 361 - 370
  • [32] Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis
    Zhang, Xuexue
    Wang, Miaoran
    Wang, Xujie
    Zhu, Zhengchuan
    Zhang, Wantong
    Zhou, Zhongyang
    Tang, Wei
    Li, Qiuyan
    ENDOCRINE PRACTICE, 2022, 28 (03) : 333 - 341
  • [33] Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
    Boye, Kristina S.
    Lage, Maureen J.
    Kiljanski, Jacek
    DIABETES THERAPY, 2021, 12 (05) : 1463 - 1474
  • [34] Haemostasiologic effects of various glucose-lowering medications in type 2 diabetes mellitus.
    Petrik, G. G.
    Pavlishchuk, S. A.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2010, 9 (02): : 48 - 53
  • [35] Exploring the impact of type 2 diabetes and glucose-lowering drugs on gut microbiome dynamics
    Hafiz Muhammad Adnan Tariq
    Nayyab Younas Khan
    Haseeb Manzoor
    Masood Ur Rehman Kayani
    Discover Medicine, 2 (1):
  • [36] Management of Glucose-Lowering Therapy in Older Adults with Type 2 Diabetes: Challenges and Opportunities
    Doucet, Jean
    Gourdy, Pierre
    Meyer, Laurent
    Benabdelmoumene, Nabil
    Bourdel-Marchasson, Isabelle
    CLINICAL INTERVENTIONS IN AGING, 2023, 18 : 1687 - 1703
  • [37] Patterns of glucose-lowering therapies and neonatal outcomes in the treatment of gestational diabetes in Canada, 2009-2014
    Bowker, S. L.
    Savu, A.
    Yeung, R. O.
    Johnson, J. A.
    Ryan, E. A.
    Kaul, P.
    DIABETIC MEDICINE, 2017, 34 (09) : 1296 - 1302
  • [38] Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer
    Holden, S. E.
    Jenkins-Jones, S.
    Morgan, C. Ll.
    Schernthaner, G.
    Currie, C. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04) : 350 - 362
  • [39] Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
    Ekstrom, Nils
    Svensson, Ann-Marie
    Miftaraj, Mervete
    Franzen, Stefan
    Zethelius, Bjorn
    Eliasson, Bjorn
    Gudbjornsdottir, Soffia
    DIABETES OBESITY & METABOLISM, 2016, 18 (10) : 990 - 998
  • [40] Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review
    Abdi, Hengameh
    Azizi, Fereidoun
    Amouzegar, Atieh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 16 (02)
12345